Astrazeneca Ab

Leonie Campbell

Michael James Waring

Roger John Butlin

Kurt G Pike

Paul Michael Murray

Alan Martin Birch

Andrew Leach

Ulrik Jurva

Stuart Norman Lile Bennett

Per Olof Ryberg

Christer Ralf Westerlund

Rolf Peter Walker

Graeme Richard Robb

Clive Green

Peter Gustaf Bonn

Anette Marie Svensson Henriksson

Abid Suleman

Robert Darren Morse Davies

Helen Claire Pointon

Mikael Dan Brink

Jonas Rickard Fägerhag

Volker Schnecke

DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro-drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity 

Substituted pyrazines as DGAT-1 inhibitors

A compound of Formula (I): is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.

Therapeutic agents

The invention relates to a novel group of compounds of Formula (I) or a salt thereof: wherein R, A and HET-1 are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK) such as type 2 diabetes. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by GLK using said compounds and methods for preparing compounds of Formula (I).

Chemical compounds

Growing community of inventors

Macclesfield, United Kingdom

Leonie Campbell